|
FIG 4. Serial rCBV measurements at each follow-up examination for all patients receiving thalidomide and carboplatin. The interval between each examination varied from 2 to 3 months. The first examination was at the start of the therapy and the fifth examination was at the 12-month follow-up. The decrease in rCBV measurements between the initial and first follow-up examination was statistically significant (P = .0014)
|